This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Charles River Laboratories (CRL) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 4.78% and 1.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teladoc (TDOC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of 23.73% and 0.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River (CRL) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Charles River's (CRL) CRADLE initiative for small and large biopharmaceutical clients is anticipated to have maintained its growth momentum.
Henry Schein (HSIC) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
We expect the Condor Dental buyout to have a beneficial impact on Henry Schein's (HSIC) results in the to-be-reported quarter.
Hologic (HOLX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Hologic's (HOLX) interventional business is likely to have faced continued supply chain headwinds related to disposable biopsy needles, hampering its performance.
Abbott's (ABT) Q3 Earnings Top Estimates, 2022 EPS View Up (Revised)
by Zacks Equity Research
Abbott's (ABT) Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
IDEXX (IDXX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
IDEXX's (IDXX) CAG premium instrument placements are expected to have recorded significant growth in Q3 on the continued rise in Catalyst and premium hematology placements.
STERIS (STE) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS' (STE) Dental arm revenues are expected to have been impacted somewhat by supply chain challenges.
Abbott's (ABT) Q2 Earnings Top Estimates, 2022 EPS View Up
by Zacks Equity Research
Abbott's (ABT) Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Owing to the impact of the Russia-Ukraine war situation, supply chain constraints, as well as the inflationary situation, we expect Bio-Rad's (BIO) Life Science arm to experience a year-over-year decline.
What's in Store for Edwards Lifesciences (EW) in Q3 Earnings?
by Zacks Equity Research
Within the TAVR arm, Edwards Lifesciences (EW) is likely to have witnessed continued growth in procedures across the United States and worldwide.
Align Technology (ALGN) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Align Technology's (ALGN) Invisalign First for kids is gaining market share rapidly across all regions.
Will Boston Scientific (BSX) Beat Q3 Earnings Estimates?
by Zacks Equity Research
Boston Scientific's (BSX) top line is likely to have improved with non-COVID elective medical procedures running in a full-fledged way in the United States and across the globe.
What's in Store for Thermo Fisher (TMO) in Q3 Earnings?
by Zacks Equity Research
In terms of performance in high-growth and emerging markets, in its flagship facility for cell culture media in Grand Island, NY, Thermo Fisher (TMO) completes capacity expansion.
LabCorp (LH) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
LabCorp's (LH) growth in early development and clinical development are expected to have been offset by central labs on the account of a significant slowdown in COVID-related work.
Quest Diagnostics (DGX) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
The non-COVID base business is expected to have gained from Quest Diagnostics' (DGX) efforts to expand value-based contracts with payers.
What's in Store for Abbott Laboratories (ABT) in Q3 Earnings?
by Zacks Equity Research
Going by the industry-wide trend so far, logistical challenges and increasing unit costs might have weighed on the corporate profitability of Abbott (ABT) in Q3.
Walgreens Boots (WBA) Q4 Earnings Top, Operating Loss Concerns
by Zacks Equity Research
The U.S. Healthcare segment of Walgreens Boots (WBA) grows on key contract wins, continued partnership growth and a strong focus on execution.
Charles River's (CRL) New Launch to Boost Gene Therapy Workflow
by Zacks Equity Research
Charles River's (CRL) latest product offering is expected to streamline the pathway to GMP AAV vector manufacturing without significant process development.
Charles River (CRL) Gains From Growing Demand Amid Macro Woes
by Zacks Equity Research
Charles River (CRL) continues to expect that the growth rate will approach 20% in the second half of 2022.
Charles River (CRL) to Support Cure AP-4's Clinical Trials
by Zacks Equity Research
Charles River's (CRL) manufacturing collaboration with Cure AP-4 will support the latter's Phase I/II gene therapy trials for a rare neurodegenerative disorder.
Why Is Charles River (CRL) Down 10.7% Since Last Earnings Report?
by Zacks Equity Research
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Charles River (CRL) Business Hurt by Macro and FX Headwinds
by Zacks Equity Research
In Q2, the impact of foreign currency translation reduces Charles River's (CRL) reported revenue growth by 3.4%.